Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Vir Biotechnology, Inc. - Common Stock
(NQ:
VIR
)
5.085
-0.325 (-6.01%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 9, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vir Biotechnology, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Vir Biotechnology Announces Retirement of CEO George Scangos, Ph.D.; Appoints Marianne De Backer, MSc, Ph.D., MBA, as Successor
January 25, 2023
From
Vir Biotechnology, Inc.
Via
GlobeNewswire
2 Stocks That Could Turn $100 Into $1,000 by 2028
January 22, 2023
These growth stocks have substantial tailwinds.
Via
The Motley Fool
Vir Biotechnology to Highlight Anticipated 2023 Catalysts and Long-Term Growth Strategy at 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
Vir Biotechnology, Inc.
Via
GlobeNewswire
Vir Biotechnology Achieves Target Enrollment for Groundbreaking Phase 2 PENINSULA Trial Evaluating VIR-2482 for Prevention of Seasonal Influenza A
December 21, 2022
– Approximately 3,000 participants enrolled with initial trial data expected in mid-2023 –
From
Vir Biotechnology, Inc.
Via
GlobeNewswire
2 Fast-Growing Healthcare Stocks to Buy and Hold
December 02, 2022
The innovative companies have made great gains in a short period of time.
Via
The Motley Fool
BioNTech, Vertex Pharmaceuticals And Other Big Biotechnology Stocks From Benzinga's Most Accurate Analysts
December 02, 2022
Although US stocks closed mixed on Thursday, but healthcare stocks recorded gains, gaining over 0.2% in the previous session. Biotechnology stocks were among the top performers in the sector, adding...
Via
Benzinga
European Official Says COVID-19 Booster Uptake Disappointing In The Region
November 25, 2022
Marco Cavaleri, the European Medicines Agency's (EMA) head of health threats and vaccines strategy, said the recent uptake of COVID-19 vaccine booster doses in the region has been "rather...
Via
Benzinga
After Bill Gates Dumps Billions In Berkshire To Buy Microsoft, His Quiet Biotech Portfolio Has Made A New Trade
November 18, 2022
Bill Gates has two portfolios he makes trades from: the Bill & Melinda Gates Foundation and the Bill & Melinda Gates Foundation Trust.
Via
Benzinga
Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2022 Deloitte Technology Fast 500™
November 16, 2022
From
Vir Biotechnology, Inc.
Via
GlobeNewswire
Data From Multiple Ongoing Trials Of Vir Biotech's HBV Therapies Show Promising Action
November 07, 2022
Via
Benzinga
Why Vir Biotechnology Jumped Nearly 19% Today
November 04, 2022
A COVID-19 partnership with a major drugmaker is producing more fruit than expected.
Via
The Motley Fool
Don't Use These 5 Non-Cost Effective COVID Treatments Including Antivirals From Merck and Gilead, Britain's NICE Says
November 16, 2022
Via
Benzinga
FDA Moves Step Closer For Opioid Overdose Medication Access, Says Certain Naloxone Products Can Potentially Be Used In OTC Setting
November 15, 2022
Via
Benzinga
Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 to Achieve a Functional Cure for Chronic Hepatitis B Virus (HBV) Infection
November 06, 2022
From
Vir Biotechnology, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
November 04, 2022
Gainers
Via
Benzinga
Vir Biotech Secures US Government Contract For Influenza & Other Infectious Disease Candidates
October 04, 2022
Via
Benzinga
Why MediaAlpha Shares Jumped Around 30%; Here Are 112 Biggest Movers From Friday
November 07, 2022
Gainers
Via
Benzinga
Why Yelp Shares Are Trading Lower By 15%? Here Are 86 Stocks Moving In Friday's Mid-Day Session
November 04, 2022
Gainers
Via
Benzinga
What 5 Analyst Ratings Have To Say About Vir Biotechnology
November 04, 2022
Over the past 3 months, 5 analysts have published their opinion on Vir Biotechnology (NASDAQ:VIR) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...
Via
Benzinga
Vir Obliterates Quarterly Sales Expectations As Covid Drug Delivers Triple-Digit Growth
November 04, 2022
Sales of Vir Biotechnology and GSK's Covid antibody almost tripled sales estimates.
Via
Investor's Business Daily
Block, MasTec, Universal Display And Some Other Big Stocks Moving Higher On Friday
November 04, 2022
U.S. stocks traded higher, with the Dow Jones gaining more than 400 points on Friday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2022 Financial Results
November 03, 2022
From
Vir Biotechnology, Inc.
Via
GlobeNewswire
Earnings Scheduled For November 3, 2022
November 03, 2022
Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.
Via
Benzinga
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at AASLD’s The Liver Meeting® 2022
October 31, 2022
From
Vir Biotechnology, Inc.
Via
GlobeNewswire
Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2022 Financial Results on November 3, 2022
October 28, 2022
From
Vir Biotechnology, Inc.
Via
GlobeNewswire
Boston University's COVID-19 Created In Lab Research Comes Under Scrutiny
October 20, 2022
Boston University created an artificial form of COVID-19 in a laboratory. Now, U.S. health officials have launched an inquiry into a controversial study. The Boston University research was designed to...
Via
Benzinga
This Addiction Drug Shows Some Potential Against Long COVID Symptoms
October 19, 2022
Researchers are working on cures for long COVID. With some success, naltrexone has been used to treat pain, fatigue, and brain fog months after a coronavirus infection.
Via
Benzinga
Vir Biotechnology Announces First Patient Dosed in Groundbreaking Phase 2 Trial of VIR-2482 for Antibody Prophylaxis of Influenza A
October 18, 2022
From
Vir Biotechnology, Inc.
Via
GlobeNewswire
Vir Biotechnology to Participate in the H. C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference
October 11, 2022
From
Vir Biotechnology, Inc.
Via
GlobeNewswire
The Next Pandemic? Vir Biotechnology Just Signed A $1 Billion Deal To Work On It
October 04, 2022
BARDA will pay Vir up to $1 billion to develop its experimental treatment.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.